HER2-Negative Breast Cancer
Interim joint analysis of the ABC Trials showed invasive disease-free survival was significant for superiority of anthracycline/taxane-based chemotherapy regimens (TaxAC) relative to docetaxel plus cyclophosphamide, according to study results presented at the 2016 ASCO Annual Meeting.
The experimental drug nintedanib, in combination with standard paclitaxel chemotherapy, caused a total remission of tumors in half of patients with early stage HER2-negative breast cancer.
Evidence-based recommendations have been developed for chemotherapy and targeted therapy for women with HER2-negative advanced breast cancer.
A test of tumor microenvironment of metastasis (TMEM) predicted risk of distant metastasis in estrogen receptor-positive and HER2-negative breast cancer, according to a new study.
High intake of saturated fat increases risk of HER2-negative, ER/PR-positive disease.
Adding dasatinib to the standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer. These results of a phase 2 clinical trial were presented at the 2013 San Antonio Breast Cancer Symposium.
Adding the antibody therapy ramucirumab to docetaxel therapy did not delay disease progression for patients with HER2-negative, advanced breast cancer. These results, from a placebo-controlled, randomized, phase 3 clinical trial, were presented at the 2013 San Antonio Breast Cancer Symposium.
I-SPY 2 has yielded positive results with the first drug to complete testing during the trial. Adding carboplatin and veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer, according to results presented at the 2013 San Antonio Breast Cancer Symposium.
All persons with invasive breast cancer (early stage or recurrence) should undergo testing for human epidermal growth factor receptor 2 (HER2), and at least one tumor sample should be tested for either HER2 protein expression or HER2 gene amplification.
The monoclonal antibody trastuzumab (Herceptin) may be effective against HER2-negative breast cancers in addition to HER2-positive disease.
The protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative. The drug trastuzumab (Herceptin), which targets HER2, may have an even greater role for treating breast cancer and preventing its spread.
The definition of hormone-sensitive breast tumors known as luminals has been changed by a recent study.
A drug used for metastatic breast cancer after several previous treatments may improve survival when administered earlier in the disease course.
Newly approved for prostate cancer, enzalutamide may be useful as a therapeutic agent in breast cancer that evades other treatments.
Combining a PI3K inhibitor with a PARP inhibitor may be an effective therapy for triple-negative breast cancer, researchers have determined.
Overweight and obese women with hormone receptor (HR)-positive operable breast cancer have an increased risk of disease recurrence and death.
Metformin, prescribed to help control blood glucose levels in type 2 diabetes, may play a role in the prevention or management of breast cancer.
New research is showing that sequence and timing have significant impact on the efficacy of therapeutic regimens that include bevacizumab.
Positron emission tomography (PET) can help pinpoint a breast cancer diagnosis and predict prognosis in an aggressive form of the disease.
Two studies show improved pathologic complete response with addition of bevacizumab.
The FDA has revoked its approval of the breast cancer indication for Avastin (bevacizumab). The anti-angiogenic therapy remains indicated for some colorectal, lung, brain, and kidney cancers.
This patient fact sheet provides questions you may want to ask your doctor about the results of your diagnostic tests and explains the significance of the answers to the questions.
The Oncologic Drug Advisory Committee recommended that the FDA withdraw its approval of bevacizumab's indication for breast cancer.
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Recurrence Score Appears To Be Driving Personalized Treatment for Breast Cancer
- Smoking-related Cancer Deaths Highest in Southern United States
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|